Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Assets (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Assets for 6 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Assets fell 5.65% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 5.65% year-over-year, with the annual reading at $1.0 billion for FY2025, 5.65% down from the prior year.
  • Assets for Q4 2025 was $1.0 billion at Janux Therapeutics, down from $1.0 billion in the prior quarter.
  • The five-year high for Assets was $1.1 billion in Q4 2024, with the low at $341.5 million in Q2 2023.
  • Average Assets over 5 years is $598.4 million, with a median of $391.1 million recorded in 2021.
  • The sharpest move saw Assets surged 2242.13% in 2021, then fell 11.38% in 2023.
  • Over 5 years, Assets stood at $379.8 million in 2021, then fell by 4.16% to $364.0 million in 2022, then rose by 4.5% to $380.4 million in 2023, then surged by 179.05% to $1.1 billion in 2024, then fell by 5.65% to $1.0 billion in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $1.0 billion, $1.0 billion, and $1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.